

ASX ANNOUNCEMENT

28 June 2021

Anteris selected to present DurAVR™ in the Innovation session at TVT 2021

Brisbane, Australia and Minneapolis USA, Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company), is pleased to announce that its unique 3D single-piece Transcatheter Heart Valve DurAVR™ THV has been selected for presentation in the innovation section of TVT 2021. The selection process is highly competitive, drawing submissions from large and small companies alike in the TAVR, mitral, tricuspid, and LAA closure (Left Atrial Appendage), spaces.

Each year, the Cardiovascular Research Foundation (CRF) and the Transcatheter Valve Therapies (TVT) Structural Heart Summit convenes leaders in the field to present three days of groundbreaking clinical and scientific information. The congress also features expertly developed series in these spaces, plus late-breaking clinical science, challenging cases, and connection to a community of thought-leaders from across the globe. The Call For Innovation is a significant and high profile component of the meeting and regarded as the pre-eminent forum for introduction of new technologies that have the potential to make a significant impact to the field. The Innovation sessions are keenly watched by Key Opinion Leaders, High level industry executives and regulators from around the world such as the FDA.

The innovation presentation will focus on the benefits the DurAVR™ THV System brings to patients and heart teams around the world in providing them with an Aortic Valve Replacement that Lasts Longer and Works Better than currently available devices by delivering near-normal hemodynamics and unprecedented durability.

The presentation will be made by Dr. Paul Sorajja MD, PhD, Interventional Cardiologist at the Minneapolis Heart Institute at the Abbott Northwestern Hospital who said: “The DurAVR™ THV System uniquely combines three highly novel technologies - ADAPT® anti-calcification technology, a single piece heart valve (DurAVR™), and commissure alignment that is an inherent design for transfemoral delivery (ComASUR™).”

“Once again DurAVR™ has been acknowledged by the medical community for being highly innovative. As we continue to advance our program and gain prestigious recognition such as being accepted for this presentation, we are increasingly confident that DurAVR™ will be a major market entrant into the global TAVR market. The evidence is compelling that the DurAVR™ THV System will meet the needs for lifetime management of aortic stenosis patients by lasting the lifetime of the patient and will provide Physicians with a solution that goes beyond the current products in the market, which is essential in younger and more active patients,” said Wayne Paterson, Chief Executive Officer of Anteris.

Anteris Technologies Ltd

Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service:

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with the unique 3D single piece aortic valve design of DurAVR™, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Trina Raymond

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 401 018 828

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech